| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Peptides | Psychiatric Disorders | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Peptides | Psychiatric Disorders | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Peptides | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Altimmune, Inc.$3.05
-0.1 (-3.21%)
C 57Pipeline Score Fair Value Biotech · Commercial
Market Cap
563.98 M
EPS
-0.94
P/E Ratio
-3.09 $
Value Trade
8.67 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
16.19 M
Operating CF
-20.94 M
Total Assets
335.63 M
Total Liabilities
51.64 M
Equity
283.99 M
D/E Ratio
12,345
0 %
Week
-15.94 %
1 Month
-35.41 %
3 Month
-34.98 %
6 Month
-79.94 %
5 Year
-99.86 %
All Time
Cash Data
Cash Position
331.54 M
Monthly Burn
6.98 M
Runway
45.8 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
2.99 M
52 Week Range
2.56 - 7.73
% held by Insiders
5.56 %
% held by Institutions
52.89 %
Enterprise Value
268.24 M
Total Shares
112.78 M
Short %
45.71 %
Float Shares
104.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Altimmune, Inc.
438Total events
2Upcoming
133Tier-1 (high impact)
2012 – 2026Coverage
Upcoming catalysts 2
Event history 436
Q3 2026
Q3 2026
◆Enrollment CompletePemvidutideTrial
Enrollment completion expected in RESTORE Phase 2 trial in ALD
ALDsource ↗
Q3 2026
◆Enrollment MilestonePemvidutideTrial
Expect enrollment completion in RESTORE Phase 2 ALD trial in Q3 2026
ALDsource ↗
May 27, 2026
▲Poster PresentationPemvidutidePresentation
Poster presentation of new IMPACT Phase 2b data at EASL 2026
MASHsource ↗
May 27, 2026
May 13, 2026
May 13, 2026
▲AbstractPemvidutidePresentation
Abstract on 48-week results selected as 'Best of EASL 2026'
MASHsource ↗
May 13, 2026
▲Breakthrough Therapy DesignationPemvidutideDesignation
FDA granted Breakthrough Therapy Designation for pemvidutide in MASH
MASHsource ↗
Apr 27, 2026
Apr 22, 2026
▼Equity OfferingCorporate
Pricing of $225 million oversubscribed public offering of common stock and warrants
Apr 2026
▼Equity OfferingCorporate
Completed oversubscribed public offering for $225.0 million gross proceeds
Drug Pipeline Intelligence
C57
Pipeline Score $1.4B
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored2.6x
rNPV / MCap Top 85%
Micro Cap (rank 138 of 911)
Percentile RankAltimmune, Inc. carries a moderate pipeline score (57/100), with $3.6B risk-adjusted pipeline value, led by Pemvidutide in Alcohol Liver Disease (Phase 2), across $88B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pemvidutide Small molecule | Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | NCT05989711 | 54% | $1.7B | COMPLETED | 212 | - | - | Nov 25, 2025 | - | MEDIUM Jun 18, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pemvidutide BreakthroughFast Track | metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2b | 2026-05-28 | 27.8% for pemvidutide 1.2 mg (p 0.001); 32.4% for pemvidutide 1.8 mg (p 0.0001) Read More | Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026 Read More | |
pemvidutide BreakthroughFast Track | metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2b | 2026-05-28 | 27.8% for pemvidutide 1.2 mg (p 0.001); 32.4% for pemvidutide 1.8 mg (p 0.0001) Read More | Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026 Read More | |
pemvidutide BreakthroughFast Track | metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2b | 2026-05-28 | 27.8% for pemvidutide 1.2 mg (p 0.001); 32.4% for pemvidutide 1.8 mg (p 0.0001) Read More | Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALTPemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAI
Read more →ALTNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Altimmune, Inc. announced positive results from the IMPACT Phase 2b trial of pemvidutide, showing concurrent improvements in non-invasive tests for metabolic dysfunction-associated steatohepatitis (MASH) at 24 weeks. The findings were supported by AI-based digital pathology analyses, indicating significant antifibrotic effects. The company plans to initiate a Phase 3 trial later this year.
Read more →ALTAltimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor confere
Read more →ALTAltimmune Announces First Quarter 2026 Financial Results and Business Update
Altimmune, Inc. reported its financial results for Q1 2026, highlighting a strong cash position of $535 million. The company plans to initiate the PERFORMA Phase 3 trial for pemvidutide in the second half of 2026, following its Breakthrough Therapy Designation from the FDA. Despite a net loss of $22.6 million, Altimmune remains focused on advancing its clinical trials for serious liver diseases.
Read more →ALTAltimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune, Inc. announced that results from its IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2026. The presentation will include 48-week efficacy and safety data, selected as 'Best of EASL 2026'. Additionally, late-breaking posters will cover new findings on liver fibrosis regression and cardiovascular risk factors.
Read more →ALT▲ +6.5%on this news
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Altimmune, Inc. will report its first quarter 2026 financial results on May 13, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Altimmune is developing pemvidutide, a therapy aimed at treating serious liver diseases.
Read more →ALTAltimmune Announces First Quarter 2026 Financial Results and Business Update Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of
Altimmune, Inc. announced its financial results for Q1 2026, revealing a robust cash position of $535 million as of April 30, 2026. The company is set to initiate the PERFORMA Phase 3 trial for pemvidutide targeting metabolic dysfunction-associated steatohepatitis in the second half of 2026. CEO Jerry Durso highlighted ongoing advancements, including topline data from RECLAIM Phase 2 AUD trial and completion of enrollment in RESTORE Phase 2 ALD trial. The company continues to focus on delivering pemvidutide for patients with serious liver diseases.
Read more →ALTAltimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. has successfully closed a $225 million oversubscribed public offering to fund its upcoming Phase 3 trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The offering included shares and warrants, with significant participation from notable investors. The company plans to utilize the proceeds for trial execution and general corporate purposes, aiming to initiate the trial in the second half of 2026.
Read more →ALT▼ -16.7%on this newsshared move
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. has announced the pricing of its oversubscribed public offering, which includes 64.25 million shares of common stock and accompanying warrants, aiming to raise approximately $225 million. The offering is set to close on or about April 24, 2026, and the proceeds will primarily fund the upcoming Phase 3 trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The offering is subject to market conditions.
Read more →ALTAltimmune Announces Proposed Underwritten Public Offering of Securities
Altimmune, Inc. has announced a proposed underwritten public offering of its common stock and accompanying warrants. The proceeds from this offering will primarily fund its upcoming Phase 3 trial for metabolic dysfunction-associated steatohepatitis (MASH). The offering is subject to market conditions, and there is no guarantee of completion or specific terms.
Read more →ALT▼ -17.9%on this news
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Altimmune, Inc. reported strong financial results for Q4 and full-year 2025, highlighting a robust cash position of $274 million. The company announced the upcoming initiation of a Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) and received FDA Breakthrough Therapy Designation. Positive data from ongoing trials in alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) further emphasize the potential of pemvidutide.
Read more →ALTAltimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Altimmune, a biopharmaceutical company, will report its fourth quarter and full year 2025 financial results on March 5, 2026. The management will host a conference call to discuss these results and provide a business update. The call will be accessible via webcast, and a replay will be available for three months.
Read more →ALT▲ +9.8%on this news
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Altimmune, Inc. has successfully closed a $75 million registered direct offering of 17,045,454 shares of common stock. The proceeds will support the upcoming Phase 3 trial for pemvidutide, a therapy for metabolic dysfunction-associated steatohepatitis (MASH). This offering enhances the company's financial stability and operational flexibility, as stated by CEO Jerry Durso.
Read more →ALT▼ -17.2%on this newsshared move
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
Altimmune, Inc. has announced a registered direct offering of common stock, aiming to raise approximately $75 million. The funds will be utilized primarily for the upcoming Phase 3 trial of pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH). The offering is set to close on January 29, 2026, pending customary conditions.
Read more →ALT▲ +16.5%on this news
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Altimmune has received Breakthrough Therapy Designation from the FDA for pemvidutide, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This designation is based on promising Phase 2b trial results showing significant MASH resolution and improvements in liver health. The company plans to initiate a Phase 3 trial to further evaluate pemvidutide's efficacy.
Read more →ALT▲ +6.2%on this news
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
Altimmune announced positive results from the IMPACT Phase 2b trial of pemvidutide, showing significant improvements in non-invasive markers of liver fibrosis at 48 weeks. The treatment demonstrated continued weight loss and maintained a favorable tolerability profile. Following a productive meeting with the FDA, the company plans to advance to a Phase 3 trial for patients with MASH.
Read more →ALT▼ -22.8%on this newsshared move
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with con
Altimmune, Inc. announced positive results from the IMPACT Phase 2b trial for Pemvidutide, demonstrating significant improvements in key non-invasive markers of fibrosis over 48 weeks. The study showed ongoing weight loss without plateauing and maintained a favorable tolerability profile with low treatment discontinuation rates. The company plans to advance Pemvidutide to a registrational Phase 3 trial, having received positive feedback from the FDA. These findings suggest the potential for Pemvidutide to be an effective treatment option for patients with metabolic dysfunction-associated steatohepatitis (MASH).
Read more →ALT▼ -6.3%on this news
Altimmune Announces CEO Transition and Succession Plan
Altimmune, Inc. announced a CEO transition with Jerry Durso succeeding Vipin Garg, effective January 1, 2026. Dr. Garg will remain as an advisor until June 30, 2026. Under Garg's leadership, the company's lead candidate, pemvidutide, advanced significantly in clinical trials. Durso, with extensive experience in liver disease, aims to enhance Altimmune's growth and commercialization efforts.
Read more →ALTAltimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Altimmune, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 2:30 p.m. ET. The session will feature members of the management team in a fireside chat format. The event will be accessible via webcast on the Altimmune website, highlighting the company's focus on novel peptide-based therapeutics.
Read more →ALTAltimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
Altimmune, Inc. announced the publication of 24-week data from the IMPACT Phase 2b trial of pemvidutide, showing significant improvements in metabolic dysfunction-associated steatohepatitis (MASH). The trial demonstrated MASH resolution, weight loss, and anti-fibrotic activity. The findings will be presented at The Liver Meeting® 2025, highlighting the potential of pemvidutide in treating MASH.
Read more →ALTAltimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
Altimmune, Inc. announced positive results from the IMPACT Phase 2b trial of pemvidutide, showing significant reductions in liver fibrosis and improvements in non-invasive tests. The AI-based analysis of biopsies demonstrated compelling results, with up to 58% of patients achieving MASH resolution. The findings will be presented at The Liver Meeting 2025.
Read more →ALT▲ +5.1%on this newsshared move
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
Altimmune, Inc. reported its financial results for Q3 2025, highlighting significant advancements in its pemvidutide program for MASH and AUD. The company anticipates 48-week data from the IMPACT trial by year-end and is scheduled for an End-of-Phase 2 meeting with the FDA. Additionally, Altimmune has strengthened its leadership team with new executive appointments.
Read more →ALTAltimmune to Participate in Two Upcoming Investor Conferences
Altimmune, Inc. announced its participation in two upcoming investor conferences, where its management team will be available for one-on-one meetings. The sessions will be webcast, allowing broader access for interested investors. Altimmune focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with its lead candidate being pemvidutide.
Read more →ALTAltimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
Altimmune has successfully completed enrollment in its RECLAIM Phase 2 trial for pemvidutide, aimed at treating alcohol use disorder (AUD). The trial includes approximately 100 patients and is set to conclude with topline results expected in 2026. The company highlights the strong enthusiasm from both patients and physicians for this new treatment option.
Read more →ALTAltimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Read more →ALTAltimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Altimmune will present 24-week data from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) at The Liver Meeting® 2025. The presentations will include an oral talk and a poster showcasing AI-based analyses of liver fibrosis reduction. The company anticipates announcing 48-week data in Q4 2025.
Read more →ALTALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Altimmune, Inc. on behalf of long-term stockholders following a class action filed against the company. The investigation focuses on whether Altimmune's board breached fiduciary duties in light of disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide. The trial's analysis showed failure to achieve statistical significance, contributing to a 53.2% drop in stock price in a single day. Investors affected during the class period are encouraged to contact the firm for potential legal recourse.
Read more →ALTALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against Altimmune, Inc., concerning securities purchased between August 10, 2023, and June 25, 2025. The lawsuit follows Altimmune's release of disappointing results from the IMPACT Phase 2b MASH trial, where statistical significance was not achieved in the primary endpoint. Following these results, Altimmune's stock price plummeted by over 53% in a single day. Investors affected by these developments are encouraged to reach out to the firm to explore their options.
Read more →ALTALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm
A class action lawsuit has been initiated against Altimmune, Inc. for investors who acquired securities between August 10, 2023, and June 25, 2025. Following disappointing results from the IMPACT Phase 2b trial, which failed to achieve statistical significance, the company's stock price dropped sharply by 53.2%. Investors have until October 6, 2025, to apply to be lead plaintiffs. The law firm Bragar Eagel & Squire is urging affected investors to discuss their legal options.
Read more →ALT▼ -5.2%on this news
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Altimmune has appointed Dr. Christophe Arbet-Engels as Chief Medical Officer to lead the Phase 3 development of pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH). Dr. Arbet-Engels brings over 30 years of experience in clinical development and regulatory approvals. He succeeds Scott Harris, who will remain as a Senior Strategic Advisor until February 2026.
Read more →ALT▼ -5.2%on this newsshared move
ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit
A class action lawsuit has been filed against Altimmune, Inc. after the company reported poor results from its IMPACT Phase 2b MASH trial. The trial aimed to evaluate the efficacy of Pemvidutide but did not meet statistical significance in its primary endpoint analysis. Following the announcement, Altimmune's stock plunged from $7.71 to $3.61 in a single day, leading to significant financial losses for investors. The deadline for investors to join the lawsuit is October 6, 2025.
Read more →ALTAltimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT
Levi & Korsinsky, LLP has announced a class action lawsuit against Altimmune, Inc. following claims of securities fraud related to the company's MASH trial results. Investors are seeking to recover losses incurred between August 2023 and June 2025, particularly after a recent press release revealed disappointing outcomes from the Phase 2b MASH trial of Pemvidutide. The stock price plummeted by 53.2% as a result of these revelations, raising concerns about inflated expectations previously set by the company. Investors have until October 6, 2025, to seek lead plaintiff status in the case.
Read more →ALTALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the October 6th Deadline in the Altimmune Class Action Lawsuit
A class action lawsuit has been filed against Altimmune, Inc. for failing to meet the primary endpoint in its clinical trial for Pemvidutide. Following the release of trial results on June 26, 2025, which showed a lack of statistical significance in the findings, Altimmune's stock plummeted by over 53% in one day. The lawsuit covers investors who acquired securities during a specified period and highlights risks associated with the company's performance and communication with stakeholders.
Read more →ALTAltimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 – ALT
Levi & Korsinsky, LLP has alerted investors about a pending class action lawsuit against Altimmune, Inc. The lawsuit arises from alleged securities fraud affecting investors between August 2023 and June 2025. Following the publication of disappointing Phase 2b MASH trial results, wherein Altimmune failed to achieve statistical significance for its primary endpoint, the company's stock saw a dramatic decrease of over 53% in one day. Investors have until October 6, 2025, to claim potential compensation without any initial costs.
Read more →ALTAltimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
Altimmune has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025. With over 30 years of experience in various therapeutic areas, her leadership is expected to enhance the company's commercial strategy, particularly as it approaches Phase 3 development of pemvidutide. Richardson emphasizes the potential of pemvidutide in treating MASH and other liver-related diseases.
Read more →ALTAltimmune, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights – ALT
Altimmune, Inc. is facing a class action lawsuit for securities law violations following disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide. The trial results, published on June 26, 2025, indicated a failure to achieve statistical significance in the primary endpoint of fibrosis reduction, despite earlier optimistic projections from the company. This led to a dramatic stock price drop from $7.71 to $3.61 per share within a day. Shareholders are being encouraged to register for the class action, which has a deadline of October 6, 2025.
Read more →ALT▲ +6.7%on this news
Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights – ALT
Altimmune, Inc. is facing a class action lawsuit for securities law violations following disappointing results from its Phase 2b MASH trial of Pemvidutide. The trial failed to meet statistical significance for its primary endpoint, leading to a significant drop in the company's stock price from $7.71 to $3.61 per share in a single day. Investors who purchased shares during the specified class period from August 10, 2023, to June 25, 2025, are encouraged to contact The Gross Law Firm to discuss their rights and potential recovery options. The deadline for enrolling as a lead plaintiff is October 6, 2025.
Read more →ALTAltimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Read more →ALTAltimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT
Altimmune, Inc. is facing a class action securities lawsuit due to alleged fraud that impacted investors between August 10, 2023, and June 25, 2025. The lawsuit follows the release of disappointing results from the company's IMPACT Phase 2b trial of Pemvidutide, which failed to meet the expected statistical significance for fibrosis reduction. Consequently, Altimmune's stock experienced a dramatic decline of over 53% in a single day. Investors affected by these developments have until October 6, 2025, to seek compensation through the lawsuit.
Read more →ALTAltimmune, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ALT
Altimmune, Inc. is currently embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP, representing investors who believe they were misled about the company's financial health. The lawsuit stems from Altimmune's Phase 2b MASH trial results for Pemvidutide, which failed to achieve statistical significance, leading to a dramatic stock price drop of 53.2% in one day. The class action seeks to recover losses for those adversely affected from August 10, 2023, to June 25, 2025, allowing impacted investors to request appointment as lead plaintiff until October 6, 2025. The suit accuses Altimmune of providing inflated expectations that contributed to the loss.
Read more →ALT▲ +7.1%on this newsshared move
Altimmune Announces Second Quarter 2025 Financial Results and Business Update Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide i
Altimmune, Inc. has reported positive outcomes from its IMPACT Phase 2b trial of pemvidutide, indicating its potential as a differentiated therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The trial achieved statistically significant results in MASH resolution and weight loss after 24 weeks. The company expects to meet with the FDA for an End-of-Phase 2 discussion in Q4 2025, while cash and investments were reported at $183.1 million as of June 30, 2025. Full 48-week data from the trial is anticipated for release later this year.
Read more →ALTAltimmune Board of Directors Appoints Jerry Durso as Chairman
Altimmune Board of Directors Appoints Jerry Durso as Chairman
Read more →ALTALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Altimmune, Inc. on behalf of shareholders who incurred losses between August 10, 2023, and June 25, 2025. The lawsuit follows a publication on June 26, 2025, revealing that Altimmune's clinical trial for Pemvidutide failed to meet statistical significance in key results, leading to a drastic decline in the company's stock price. The firm is soliciting investors who may wish to participate in the legal action as lead plaintiffs.
Read more →ALTAltimmune, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 6, 2025 Deadline to file Lead Plaintiff Motion.
Altimmune, Inc. is currently facing a class action lawsuit after allegations that it misrepresented data from its IMPACT Phase 2b MASH trial. The complaint highlights that the company made overly optimistic statements despite one primary endpoint failing to meet statistical significance. Following this, Altimmune's stock plummeted by over 53% in a single day. Investors have a deadline of October 6, 2025, to file a lead plaintiff motion as they seek to recover losses incurred during the Class Period from August 10, 2023, to June 25, 2025.
Read more →ALTAltimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
Altimmune, Inc. will report its second-quarter 2025 financial results on August 12, 2025. A conference call will be held at 8:30 am E.T. to discuss these results and provide a business update. The call will be available for live streaming on Altimmune's Investor Relations website, and a replay will be accessible afterward for three months. The company is actively working on its lead program, pemvidutide, targeting liver and cardiometabolic diseases.
Read more →ALTAltimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Read more →ALT▼ -53.2%on this news
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met it
Altimmune, Inc. has announced positive topline results from its IMPACT Phase 2b trial demonstrating the efficacy of pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). A significant 59.1% of participants achieved MASH resolution without worsening fibrosis after 24 weeks, with notable weight loss and low treatment discontinuation rates. The safety profile was robust, with less than 1% of participants discontinuing due to adverse events. This progress is expected to support Altimmune's efforts toward regulatory review and potential future use in MASH treatment.
Read more →ALT▲ +7.2%on this news· ran to -50% by day 1shared move
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Altimmune, Inc. will present topline results from its IMPACT Phase 2b trial of pemvidutide, a novel therapeutic for metabolic dysfunction-associated steatohepatitis (MASH), on June 26, 2025. The trial enrolled 212 patients to evaluate the efficacy of pemvidutide compared to placebo over a 24-week period. Pemvidutide has previously demonstrated significant rates of MASH resolution and improvements in liver health. The webcast of the presentation will be available for replay on the company’s website shortly after the call.
Read more →ALTAltimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions
Read more →ALTAltimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Read more →ALTAltimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. is set to participate in two upcoming investor conferences: the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, and the Jefferies Global Healthcare Conference on June 4, 2025. The company's management team will be available for one-on-one meetings, enhancing investor engagement. Altimmune focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with its lead program, pemvidutide, addressing multiple health conditions. The sessions will be accessible via live webcast on Altimmune's website.
Read more →ALTAltimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
Read more →ALTAltimmune Announces First Quarter 2025 Financial Results and Business Update Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2
Altimmune, Inc. announced its financial results for Q1 2025, highlighting upcoming milestones, including top-line data from its IMPACT Phase 2b trial of pemvidutide expected in Q2 2025. The company has secured a $100 million credit facility to support its financial flexibility, facilitating the development of pemvidutide targeting metabolic dysfunction-associated steatohepatitis, Alcohol Use Disorder, and Alcohol Liver Disease. CEO Vipin K. Garg expressed confidence in achieving significant clinical outcomes, positioning pemvidutide as a potential leader in treating these conditions.
Read more →ALT▲ +8.2%on this newsshared move
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
Altimmune, Inc. presented new analyses at the EASL International Liver Congress indicating promising results for MASH resolution in patients treated with pemvidutide, its dual GLP-1/glucagon receptor agonist. The MASH Resolution Index predicts high rates of resolution following 24 weeks of treatment, with significant response rates reported. The results bolster expectations for the ongoing IMPACT Phase 2b Trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD). Altimmune's clinical focus encompasses various indications, including obesity and alcohol use disorder.
Read more →ALT▼ -7.4%on this newsshared move
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
Altimmune, Inc. has announced that it will report its first quarter 2025 financial results on May 13, 2025. The company will hold a conference call at 8:30 am E.T. on the same day to discuss these results and provide a business update to stakeholders. The call will be available for live streaming and will also have a replay option for three months. Altimmune is focused on developing advanced peptide-based therapeutics, particularly the dual receptor agonist pemvidutide aimed at treating various conditions including obesity and alcohol-related disorders.
Read more →ALTAltimmune to Present at Upcoming EASL International Liver Congress 2025
Altimmune to Present at Upcoming EASL International Liver Congress 2025
Read more →ALTAltimmune to Participate in the Citizens Life Sciences Conference
Altimmune to Participate in the Citizens Life Sciences Conference
Read more →ALTAltimmune to Host Virtual R&D Day on March 13, 2025
Altimmune to Host Virtual R&D Day on March 13, 2025
Read more →ALT▼ -9.9%on this newsshared move
Altimmune to Participate in the Leerink Global Healthcare Conference
Altimmune to Participate in the Leerink Global Healthcare Conference
Read more →ALT▲ +8.1%on this newsshared move
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to
Altimmune reported its financial results for Q4 and the full year 2024, highlighting significant advancements in its pemvidutide program for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company is on track to present top-line data from the Phase 2b IMPACT trial in Q2 2025 and has received FDA clearance for two new IND applications, with Phase 2 trials expected to begin in mid-2025. Furthermore, Altimmune's financial health is robust, boasting $131.9 million in cash as of December 31, 2024.
Read more →ALTSeasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson re
Altimmune has appointed Teri Lawver and Jerry Durso to its Board of Directors, bringing extensive biopharmaceutical experience to the company. Lawver, formerly of Dexcom and Johnson & Johnson, contributes significant expertise in commercialization and global strategy, while Durso has a strong background from Intercept Pharmaceuticals and Sanofi. Their appointments come as Altimmune prepares for late-stage clinical development of pemvidutide, a promising therapeutic candidate aimed at obesity and liver diseases. Both executives expressed enthusiasm about helping guide the company's transition towards commercialization.
Read more →ALTAltimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
Altimmune, Inc. will report its fourth quarter and full year 2024 financial results on February 27, 2025. The company's management will discuss these results and provide a business update during a conference call scheduled for 8:30 am ET on the same day. The call will be accessible via webcast on Altimmune's Investor Relations website. Altimmune is focusing on developing next-generation peptide-based therapeutics, including pemvidutide for obesity treatment.
Read more →ALTAltimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Read more →ALTAltimmune Added to Nasdaq Biotechnology Index
Altimmune Added to Nasdaq Biotechnology Index
Read more →ALTAltimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Read more →ALT▼ -10%on this news
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024
Read more →ALT▲ +29.1%on this newsshared move
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line ef
Altimmune, Inc. announced its financial results for Q3 2024 along with key business updates. The company completed enrollment in its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, with top-line efficacy data expected in Q2 2025. Additionally, Altimmune successfully concluded an End-of-Phase 2 meeting with the FDA, obtaining agreement on the pivotal study designs for the obesity program. The firm is also gearing up to submit IND applications for multiple indications of pemvidutide by the end of 2024, suggesting strong future prospects for the drug.
Read more →ALTAltimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Altimmune, Inc. announced the granting of equity awards to Gregory Weaver, who has been appointed as the Chief Financial Officer effective November 11, 2024. The grants were made under the company's 2018 Inducement Grant Plan and were approved by the Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). Weaver's compensation package includes options to purchase 225,000 shares and 75,000 restricted stock units, with vesting tied to his continued employment. Altimmune is recognized for its work on next-generation peptide-based therapeutics, including the development of pemvidutide for obesity treatment.
Read more →ALTAltimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer GAITHERSBURG, MD
Altimmune, Inc. has announced the appointment of Greg Weaver as Chief Financial Officer, effective immediately. With over 25 years of experience in finance within life sciences, Weaver is expected to play a critical role during a pivotal time for the company as it develops its lead product, pemvidutide. Weaver expressed optimism about the product's therapeutic potential for treating obesity and liver disorders. He has a track record in leading financial operations in various biotech firms, which may enhance Altimmune's strategic initiatives.
Read more →ALTAltimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Read more →ALTAltimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Altimmune, Inc. has announced that it will report its third quarter financial results on November 12, 2024, along with a business update. The conference call will be hosted by management at 8:30 am E.T. and will be available via live webcast. Altimmune is focusing on developing peptide-based therapeutics, particularly pemvidutide, targeting obesity and MASH.
Read more →ALT▲ +9.5%on this news
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024
Read more →ALTAltimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Altimmune, Inc. announced its participation in the H.C. Wainwright 8th Annual MASH Virtual Conference, where CEO Vipin Garg and CMO Scott Harris will present. The conference is scheduled for October 7, 2024, at 11:30 a.m. EDT. This indicates Altimmune's active engagement in the biopharmaceutical community and its focus on developing peptide-based therapeutics, including pemvidutide, aimed at treating obesity and metabolic dysfunction-associated steatohepatitis.
Read more →ALT▼ -5.1%on this newsshared move
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Read more →ALT▲ +9.1%on this news· ran to +24% by day 3
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Read more →ALTAltimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune, Inc. announced that findings from its Phase 2, MRI-based body composition sub-study of pemvidutide will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid. Pemvidutide is an investigational dual receptor agonist targeting obesity and metabolic dysfunction-associated steatohepatitis. The drug has shown significant benefits in weight loss and metabolic health in previous clinical trials, leading to its Fast Track designation by the FDA. The presentation will showcase how pemvidutide helps preserve lean body mass during weight loss in overweight and obese patients.
Read more →ALT▲ +15.1%on this news
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and
Altimmune, Inc. reported its financial results for Q2 2024, highlighting the progress of pemvidutide in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company noted recent positive presentations at major medical meetings supporting pemvidutide's therapeutic potential. Enrollment for the Phase 2b IMPACT trial is ongoing, with topline data anticipated in Q1 2025. Despite significant cash reserves, Altimmune reported a net loss of $24.6 million during the quarter, accompanied by rising operating expenses.
Read more →ALTAltimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Read more →ALT▲ +6.7%on this news
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune, Inc. has published promising results from a clinical study of pemvidutide for treating metabolic dysfunction-associated steatotic liver disease (MASLD) in the Journal of Hepatology. The study indicated that 68.5% of participants on pemvidutide experienced reductions in liver fat content, with 55.6% achieving normalization after 12 weeks. Additionally, participants demonstrated significant improvements in body weight and liver inflammation markers. The drug is currently being further evaluated in the Phase 2b IMPACT trial, with data expected in Q1 2025.
Read more →ALTALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Altimmune, Inc. for alleged misleading statements regarding its lead product, pemvidutide. The lawsuit pertains to statements made during the specified class period about the drug's efficacy and the company's market prospects. Following negative analyst reports and downgrades, Altimmune's stock price has experienced significant declines, raising concerns regarding its ability to secure necessary partnerships for drug development. Investors are encouraged to reach out to the law firm for further participation in the lawsuit.
Read more →ALT▼ -6.4%on this newsshared move
Altimmune to Participate at Leerink Partners Therapeutics Forum
Altimmune to Participate at Leerink Partners Therapeutics Forum
Read more →ALT▼ -6.4%on this newsshared move
Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
A class action lawsuit has been filed against Altimmune, Inc. on behalf of investors who have incurred losses. The lawsuit claims that the company misrepresented the efficacy and commercial potential of its drug, pemvidutide, during the MOMENTUM Trial. These misrepresentations allegedly led investors to hold a falsely optimistic view of the company's prospects and strategic partnerships. Investors are advised to contact The Portnoy Law Firm for recovery options.
Read more →ALT▲ +8.3%on this newsshared move
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
Altimmune, Inc. is facing a class action lawsuit after allegations emerged that the company overstated the potential of its lead drug candidate, pemvidutide. The lawsuit claims violations of the Securities Exchange Act, particularly related to misleading statements about the drug's efficacy compared to competitors. Following a report that deemed pemvidutide less competitive, Altimmune's stock price suffered a significant decline. Investors are reminded of the upcoming deadline to file a lead plaintiff motion in the case, with options to discuss their legal rights.
Read more →ALT▼ -15.6%on this newsshared move
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt GAITHERSBURG, MD
Altimmune, a clinical-stage biopharmaceutical company, announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. The company's president expressed shock and condolences to Eisenstadt's family, highlighting his leadership and contributions. Until a replacement is appointed, the finance and accounting team will manage Eisenstadt's responsibilities. Altimmune is actively searching for his successor during this difficult time.
Read more →ALT▲ +11.4%on this newsshared move
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions
Read more →ALT▲ +11.4%on this newsshared move
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions
Read more →ALTALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
Robbins LLP has announced a pending lead plaintiff deadline for a class action lawsuit against Altimmune, Inc., filed by investors who purchased securities between December 1, 2023, and April 26, 2024. The lawsuit alleges that Altimmune misled investors about the effectiveness and market potential of its weight loss drug, pemvidutide, based on results from the MOMENTUM Trial. Reports from Kerrisdale Capital and Guggenheim Securities have suggested that pemvidutide may struggle to compete in the market, resulting in significant stock price declines. Shareholders interested in participating in the lawsuit must file motions by July 5, 2024.
Read more →ALTAltimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
Read more →ALTAltimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
Read more →ALTALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.
Bernstein Liebhard LLP has announced a securities class action lawsuit filed against Altimmune, Inc. on behalf of shareholders who acquired stocks between December 1, 2023, and April 26, 2024. The lawsuit alleges that Altimmune misled investors about the potential advantages of its drug pemvidutide over competing GLP-1 agonists. Following the release of detrimental information regarding pemvidutide’s effectiveness and the likelihood of finding a developmental partner, Altimmune's stock has suffered substantial losses.
Read more →ALT▼ -7.8%on this newsshared move
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights – ALT
Altimmune, Inc. (NASDAQ: ALT) is facing a class action lawsuit alleging securities fraud due to misleading statements related to its lead product candidate, pemvidutide. The lawsuit claims the company overstated the drug's potential and efficacy in comparison to competing therapies. This has led to questions regarding Altimmune's market position and prospects for securing a strategic partner. Shareholders who purchased stock within the specified class period are encouraged to register for participation in the lawsuit before the July 5, 2024 deadline.
Read more →ALTAltimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Read more →ALTAltimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024
Read more →ALT▲ +13.4%on this news
Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action
Robbins LLP has announced a class action against Altimmune, Inc. on behalf of investors who acquired the company's stock between December 1, 2023, and April 26, 2024. The action follows allegations that Altimmune misrepresented the efficacy and potential competitive standing of its weight loss drug, pemvidutide, leading to significant stock declines. Following negative assessments by analysts, including Kerrisdale Capital and Guggenheim Securities, Altimmune's stock prices dropped significantly. Shareholders may apply to be lead plaintiffs by July 5, 2024.
Read more →ALTALTIMMUNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
Rosen Law Firm has filed a class action lawsuit on behalf of Altimmune, Inc. investors who purchased securities between December 1, 2023 and April 26, 2024. The lawsuit alleges that the company's statements regarding its lead product candidate, pemvidutide, were misleading, particularly concerning its competitive prospects in the market. Investors may be eligible for compensation, and a lead plaintiff must be appointed by July 5, 2024. The firm emphasizes the importance of selecting qualified legal counsel for this matter.
Read more →ALT▲ +7.8%on this newsshared move
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line
Altimmune, Inc. reported its financial results for Q1 2024, revealing a net loss of $24.4 million while maintaining a cash position of $182.1 million. The company provided an update on its ongoing Phase 2b trial of pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025. The FDA has granted Fast Track designation for pemvidutide, which is also in the final stages of preparation for an End-of-Phase 2 meeting. Optimistically, pemvidutide has shown significant efficacy in weight loss and metabolic improvement during trials.
Read more →ALTAltimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit
A securities fraud lawsuit has been filed against Altimmune, Inc. and its executives, following a drop in stock value attributed to poor tolerability of its GLP-1 drug and the diminished likelihood of forming a strategic partnership. Investors who lost money between December 01, 2023, and April 26, 2024, are encouraged to contact the legal firm Block & Leviton for potential recovery options. The lawsuit alleges that Altimmune misrepresented its capabilities related to the drug's commercial prospects. The deadline for investors to seek appointment as lead plaintiff is set for July 05, 2024.
Read more →ALTAltimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Read more →ALT▲ +7.9%on this newsshared move
Altimmune to Participate at Two Upcoming Conferences
Altimmune to Participate at Two Upcoming Conferences
Read more →ALTAltimmune Statement on the Passing of Dr. Stephen Harrison
Altimmune Statement on the Passing of Dr. Stephen Harrison
Read more →ALTAltimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results Body composition study showed lean mass preservation, with only 25.5% of weight los
Altimmune, Inc. has reported promising results from its Phase 2 obesity trial of pemvidutide, indicating a favorable body composition outcome with 74.5% of weight loss attributed to fat rather than lean mass. The company has significant cash reserves totaling $198 million and is actively pursuing ongoing trials, including the IMPACT Phase 2b trial for metabolic dysfunction-associated steatohepatitis. However, the company halted development of the HepTcell therapy due to insufficient trial outcomes. Overall, pemvidutide's progress positions Altimmune favorably in the competitive obesity treatment market.
Read more →ALT▲ +6.9%on this news
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Read more →ALT▼ -6.5%on this news
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Read more →ALTAltimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end
Altimmune, Inc. has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The study, which included 391 subjects, demonstrated significant weight loss, especially with the 2.4 mg dose, where participants achieved a mean weight loss of 15.6%. Moreover, the treatment not only led to weight loss but also improved serum lipids and blood pressure with a reassuring safety profile. The findings suggest that pemvidutide could be a promising option for obesity management.
Read more →ALTAltimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the
Altimmune, Inc. announced its financial results for Q3 2023, showing a net loss of $20.7 million. The company highlighted the upcoming 48-week results from the MOMENTUM Phase 2 obesity trial and expressed optimism about receiving Fast Track designation for its pemvidutide treatment for NASH. Additionally, top-line results from the Phase 2 trial of HepTcell in chronic hepatitis B are expected in Q1 2024. Despite significant losses, Altimmune continues to focus on addressing critical health issues related to obesity and liver diseases.
Read more →ALTAltimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
Read more →ALTAltimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Read more →ALTAltimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023
Read more →ALTAltimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
Altimmune, Inc. announced that Dr. Louis J. Aronne will present the results of a 24-week clinical trial of pemvidutide at the 59th Annual Meeting of the European Association for the Study of Diabetes. Pemvidutide, a novel peptide-based GLP-1/glucagon dual receptor agonist, aims to treat obesity and non-alcoholic steatohepatitis (NASH). The oral presentation is scheduled for October 3, 2023, and emphasizes the drug's potential in mimicking diet and exercise effects on weight loss while enhancing liver fat metabolism.
Read more →ALT▲ +7.4%on this news· ran to +20% by day 3
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Read more →ALTAltimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment in IMPACT Phase 2b trial of
Altimmune, Inc. reported its financial results for Q2 2023 and announced key developments in its clinical trials. The company has commenced enrollment in its IMPACT Phase 2b trial for pemvidutide focusing on non-alcoholic steatohepatitis (NASH) and anticipates top-line results from its MOMENTUM Phase 2 obesity trial in Q4 2023. The firm highlighted positive Phase 1b data, supporting expectations for significant efficacy in both obesity and NASH conditions. Despite these advancements, Altimmune reported a net loss of $16,061, raising concerns about its ongoing financial sustainability.
Read more →ALTAltimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Read more →ALTAltimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Read more →ALTAltimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
Read more →ALTAltimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
Altimmune, Inc. announced that Dr. Stephen A. Harrison will present findings from a 24-week clinical trial of pemvidutide for treating non-alcoholic fatty liver disease (NAFLD) at the EASL International Liver Congress 2023 in Vienna, Austria. The presentation will highlight significant reductions in liver fat, fibro-inflammation, and body weight in patients throughout the trial duration. Furthermore, this presentation has been selected for the prestigious Best of EASL Summary Slides, emphasizing its importance in the conference agenda. Altimmune will also host a reception for key opinion leaders and investors during the congress.
Read more →ALT▲ +7%on this news
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week re
Altimmune, Inc. has reported its financial results for Q1 2023 and provided updates on its clinical trials. The initiation of the Phase 2b IMPACT trial for pemvidutide in non-alcoholic steatohepatitis (NASH) is expected mid-2023, following promising results in prior studies. The company anticipates top-line results from the MOMENTUM Phase 2 obesity trial in Q4 2023 and HepTcell Phase 2 trial results in early 2024. However, Altimmune faces financial losses and uncertainties related to the success of its product candidates.
Read more →ALTAltimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Read more →ALTAltimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B
Read more →ALT▲ +11.6%on this news
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
Altimmune has appointed Catherine Angell Sohn, Pharm.D., to its Board of Directors, enhancing its leadership team. Dr. Sohn's extensive experience in the pharmaceutical industry, particularly in strategic development and commercialization, is expected to aid Altimmune in its goal of developing peptide therapeutics for obesity and liver disease. She has held significant positions at various leading companies and is recognized for her contributions to the industry. The move signals Altimmune's commitment to leveraging high-level expertise as it advances its innovative therapeutic pipeline.
Read more →ALT▼ -54.7%on this news
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis
Altimmune, Inc. announced positive interim results from the Week 24 analysis of its MOMENTUM Phase 2 obesity trial and the Phase 1b safety trial for pemvidutide. The trials, involving a total of 160 subjects for the interim analysis, demonstrated significant weight loss in participants receiving pemvidutide compared to placebo. Additionally, improvements in waist circumference, serum lipids, and blood pressure were noted, despite some mild gastrointestinal adverse events. These outcomes suggest a strong potential for pemvidutide as a treatment for obesity and related conditions, with further trials planned to explore higher doses.
Read more →ALT▲ +6.4%on this news
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic
Altimmune, Inc. has reported its financial results for the fourth quarter and full year ended December 31, 2022, highlighting key business updates. The company anticipates the release of interim results from the MOMENTUM Phase 2 obesity trial later in March 2023 and plans to initiate a Phase 2b trial for non-alcoholic steatohepatitis (NASH) in mid-2023. Pemvidutide, their dual-receptor agonist, is noted for its promising attributes in treating obesity and liver diseases. Despite operational losses, the company is focused on significant upcoming milestones in its clinical developments.
Read more →ALT▼ -5.3%on this news
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
Read more →ALT▼ -5.2%on this news
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
Altimmune, Inc. announced that Dr. Stephen A. Harrison will present data from recent Phase 1b trials of pemvidutide at the NASH-TAG Conference on January 7, 2023. The study focuses on the treatment of non-alcoholic fatty liver disease (NAFLD), highlighting significant findings in reducing liver fat and body weight. Pemvidutide is a dual receptor agonist developed for obesity and NASH, showcasing the company's advancements in peptide-based therapeutics.
Read more →ALT▼ -5.2%on this news
Altimmune Appoints Raymond Jordt as Chief Business Officer
Altimmune Appoints Raymond Jordt as Chief Business Officer
Read more →ALT▲ +16%on this news· ran to +49% by day 3
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) Greater than 75% relative reduction in liver fat content achie
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) GAITHERSBURG, MD, -- December 20, 2022 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, toda
Read more →ALT▲ +9.2%on this news
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Inter
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial exp
Read more →ALTAltimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
Read more →ALTAltimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting
Read more →ALT▲ +13.2%on this news
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Read more →ALT▼ -27%on this news
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved t
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD GAITHERSBURG, MD, -- September 14, 2022 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today an
Read more →ALT▲ +7.1%on this news· ran to +37% by day 3
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update Topline data from 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update Topline data from 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected mid-September 2022 GAITHERSBURG, MD, -- August 11, 2022 -
Read more →ALTAltimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
Read more →ALT▲ +22.9%on this news· ran to +44% by day 3
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Read more →ALTAltimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medici
Read more →ALTAltimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27,
Read more →ALT▼ -6.8%on this news
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global
Read more →ALT▲ +8.6%on this news· ran to +34% by day 3shared move
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update Multiple clinical trial data readouts expected in Q3 and Q4 2022 GAITHERSBURG, MD
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update Multiple clinical trial data readouts expected in Q3 and Q4 2022 GAITHERSBURG, MD, -- May 12, 2022 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announ
Read more →ALT▼ -6.2%on this news
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Read more →ALTAltimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
Read more →ALT▼ -8.2%on this news
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 mil
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 million as of December 31, 2021 GAITHERSBURG, MD, -- March 1
Read more →ALTAltimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Read more →ALT▲ +12.1%on this news
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Read more →ALTAltimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
Read more →ALTAltimmune Appoints Richard Eisenstadt as Chief Financial Officer GAITHERSBURG, MD
Altimmune Appoints Richard Eisenstadt as Chief MD, -- December 13, 2021 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief F
Read more →ALTAltimmune to Present at Upcoming Investor and Scientific Conferences
GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences: Piper Sandler 33rd Annual Virt
Read more →ALTAltimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of trea
Read more →ALTAltimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
Read more →ALTAltimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
Read more →ALT▼ -5.3%on this newsshared move
Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
Read more →ALT▼ -13.8%on this newsshared move
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
Read more →ALTAltimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dose Pemvidutide was we
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers GAITHERSBURG, Md., September 28, 2021 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive result
Read more →ALTAltimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Read more →ALTAltimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Read more →ALTAltimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update 12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218 Million in Cash and Short-Term I
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update 12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline
Read more →ALTAltimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
Read more →ALTAltimmune Announces Update on AdCOVID Phase 1 Clinical Trial
Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial
Read more →ALTAltimmune Announces Update on AdCOVID TM Phase 1 Clinical Trial AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers Altimmune will discontinue further development of AdCOVID
Update on AdCOVIDTM Phase 1 Clinical Trial AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs Altimmune a
Read more →ALTAltimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers GAITHERSBURG, MD, June 16, 2021 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim anal
Read more →ALTAltimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
Read more →ALTAltimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID
Read more →ALTAltimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update Data Readouts from Phase 1 AdCOVID and ALT-801 Clinical Trials Expected in June Approximately $227 Million in Cash and Short-Term I
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update Data Readouts from Phase 1 AdCOVID and ALT-801 Clinical Trials Expected in June Approximately $227 Million in Cash and Short-Term Investments to Advance Pipeline GAITHERSBURG, MD, -- May
Read more →ALTAltimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
Read more →ALTAltimmune Announces New Preclinical Data for AdCOVID Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Altimmune Announces New Preclinical Data for AdCOVID Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Read more →ALTAltimmune to Present at Upcoming Scientific Conferences
Altimmune to Present at Upcoming Scientific Conferences
Read more →ALTAltimmune Reports Data from its Phase 1b Clinical Trial of NasoShield GAITHERSBURG, MD
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield GAITHERSBURG, MD, April 1, 2021 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b tri
Read more →ALTAltimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID Vaccine Candidate
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID Vaccine Candidate
Read more →ALTAdCOVID, Altimmune's Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
AdCOVID, Altimmune's Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
Read more →ALTAltimmune Expands AdCOVID Manufacturing Collaboration with Lonza Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune s COVID-19 Vaccine Candidate at its Houston Facility GAITHERSBURG, Ma
Altimmune Expands AdCOVID Manufacturing Collaboration with Lonza Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune s COVID-19 Vaccine Candidate at its Houston Facility GAITHERSBURG, Maryland (USA) and Basel, Switzerland, March 12, 2021 Altim
Read more →ALTAltimmune to Present at Upcoming Conferences
Altimmune to Present at Upcoming Conferences
Read more →ALTAltimmune Announces Financial Results for the Year Ended
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update Enrollment in the Phase 1 AdCOVID Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun ALT-801 is Pr
Read more →ALTAltimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Read more →ALTAltimmune To Announce Year End 2020 Financial Results on February 25, 2021
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
Read more →ALTAltimmune Announces FDA Clearance of AdCOVID IND Application
Altimmune Announces FDA Clearance of AdCOVID IND Application
Read more →ALTAltimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
Read more →ALTAltimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID Clinical Trial GAITHERSBURG, MD
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID Clinical Trial GAITHERSBURG, MD, December 23, 2020 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administrati
Read more →ALTAltimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
Read more →ALTAltimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
Read more →ALTAltimmune Announces Submission of Investigational New Drug Application for AdCOVID a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
Read more →ALTAltimmune to Present at Upcoming Virtual Investor Conferences
Altimmune to Present at Upcoming Virtual Investor Conferences
Read more →ALTAltimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19
Read more →ALTAltimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, MD
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, MD, November 9, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended Septemb
Read more →ALTAltimmune to Announce Third Quarter 2020 Financial Results on November 10
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
Read more →ALTAltimmune to Present at Two Upcoming Virtual Investor Conferences
Altimmune to Present at Two Upcoming Virtual Investor Conferences
Read more →ALTAltimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID Intranasal COVID-19 Vaccine Candidate
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID Intranasal COVID-19 Vaccine Candidate
Read more →ALTAltimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs - AdCOVID and T-COVID - at the World Vaccine Congress
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs - AdCOVID and T-COVID - at the World Vaccine Congress
Read more →ALTAltimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH
Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH
Read more →ALTAltimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress 2020
Altimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress 2020
Read more →ALTAltimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID™
GAITHERSBURG, Md., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced additional positive results from the preclinical studies of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. The studies
Read more →ALTAltimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, Maryland, August 11, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended Jun
Read more →ALTAltimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate
Read more →ALTAltimmune to Announce Second Quarter 2020 Financial Results on August 12
Altimmune to Announce Second Quarter 2020 Financial Results on August 12
Read more →ALTAltimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID, its Single Dose Intranasal Vaccine Candidate for COVID-19
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID, its Single Dose Intranasal Vaccine Candidate for COVID-19
Read more →ALTAltimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters Option
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters Option
Read more →ALTAltimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
Read more →ALTAltimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GAITHERSBURG, Md.
Altimmune Announces Proposed Public Offering of Common Stock and GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other condition
Read more →ALTAltimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID TM AdCOVID stimulated both strong serum neutralizing activity and poten
Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVIDTM AdCOVID stimulated both strong serum neutralizing activity and potent mucosal immunity (IgA) in the respiratory tract GAITHERSB
Read more →ALTAltimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID
Read more →ALTAltimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate
Read more →ALTAltimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID in Outpatients with Early COVID-19
Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID in Outpatients with Early COVID-19
Read more →ALTAltimmune Announces IND Clearance for a Phase 2 Trial of HepTcell Immunotherapeutic for the Treatment of Chronic Hepatitis B
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell Immunotherapeutic for the Treatment of Chronic Hepatitis B
Read more →ALTAltimmune Launches Clinical Trial of T-COVID TM , an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19 Clearance of IND application received from the U.S. FDA Planned Phase 1/2
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients GAITHERSBURG, MD, June 1, 2020 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the U.S. Food
Read more →ALTAltimmune Launches Clinical Trial of T-COVID, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
Altimmune Launches Clinical Trial of T-COVID, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
Read more →ALTAltimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
Clearance of IND application received from the U.S. FDA Planned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection Placebo-controlled trial expected to commence in June with data readout expected in Q4 2020 Therapeutic development progra
Read more →ALTAltimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, Maryland, May 13, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and p
Read more →ALTAltimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors GAITHERSBURG, Maryland, May 12, 2020 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board
Read more →ALTAltimmune to Announce First Quarter 2020 Financial Results on May 14
Altimmune to Announce First Quarter 2020 Financial Results on May 14
Read more →ALTAltimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
Read more →ALTAltimmune to Announce Year End 2019 Financial Results on March 27
Altimmune to Announce Year End 2019 Financial Results on March 27
Read more →ALTAltimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
Read more →ALTAltimmune to Present at the Cowen 40th Annual Health Care Conference
Altimmune to Present at the Cowen 40th Annual Health Care Conference
Read more →ALTAltimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
Read more →ALTAltimmune to Present at the 2020 NASH-TAG Conference
Altimmune to Present at the 2020 NASH-TAG Conference
Read more →ALTAltimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
Read more →ALTAltimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update Conference Call & Webcast Scheduled for Thursday, November 14, at 8:30am Eastern Time
Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update Conference Call & Webcast Scheduled for Thursday, November 14, at 8:30am Eastern Time GAITHERSBURG, Maryland, November 13, 2019 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceu
Read more →ALTAltimmune to Announce Third Quarter 2019 Financial Results on November 14
Altimmune to Announce Third Quarter 2019 Financial Results on November 14
Read more →ALTAltimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
Read more →ALTAltimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield Clinical Development Phase 1b clinical trial will study effect of dosing methodology on immune response to intranasal anthrax vaccine GAI
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield Clinical Development Phase 1b clinical trial will study effect of dosing methodology on immune response to intranasal anthrax vaccine GAITHERSBURG, MD, August 21, 2019 Altimmune, Inc. (Nasdaq:
Read more →ALTAltimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update Conference Call & Webcast Scheduled for Wednesday, August 14, at 8:30am Eastern Time
Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update Conference Call & Webcast Scheduled for Wednesday, August 14, at 8:30am Eastern Time GAITHERSBURG, Maryland, August 13, 2019 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceuti
Read more →ALTAltimmune to Announce Second Quarter 2019 Financial Results on August 14
Altimmune to Announce Second Quarter 2019 Financial Results on August 14
Read more →ALTAltimmune Announces Closing of Acquisition of Spitfire Pharma, Inc. GAITHERSBURG, MD
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc. GAITHERSBURG, MD, July 15, 2019 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma
Read more →ALTAltimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunctio
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to GAITHERSBURG, MD, July 9, 2019 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement t
Read more →ALTAltimmune Appoints Will Brown as Chief Financial Officer
Altimmune Appoints Will Brown as Chief Financial Officer GAITHERSBURG, Maryland, June 12, 2019 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Ac
Read more →ALTAltimmune Announces Successful Pre-IND Meeting with FDA
Altimmune Announces Successful Pre-IND Meeting with FDA
Read more →ALTAltimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
Read more →ALTAltimmune Announces First Quarter 2019 Financial Results and Provides a Business Update Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time GAITHERSBURG, Maryland, May 14, 2019 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics co
Read more →ALTAltimmune to Announce First Quarter 2019 Financial Results on May 15
Altimmune to Announce First Quarter 2019 Financial Results on May 15
Read more →ALTAltimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
Read more →ALTAltimmune to Announce Year End 2018 Financial Results on April 2
Altimmune to Announce Year End 2018 Financial Results on April 2
Read more →ALTAltimmune Announces Positive Results from NasoVAX Extension Study
Altimmune Announces Positive Results from NasoVAX Extension Study
Read more →ALTAltimmune to Participate at 31st Annual ROTH Conference
Altimmune to Participate at 31st Annual ROTH Conference
Read more →ALTAltimmune Announces Closing of $14 Million Registered Direct Offering
Altimmune Announces Closing of $14 Million Registered Direct Offering
Read more →ALTAltimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expa
Read more →ALTAltimmune Announces $14 million Registered Direct Offering
Altimmune Announces $14 million Registered Direct Offering GAITHERSBURG, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two institutional investors
Read more →ALTAltimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress in Vienna, Austria
Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress in Vienna, Austria
Read more →ALTAltimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a clinical-stage immunotherapeutics company, granted equity awards on November 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Altimmune’s 201
Read more →ALTAltimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer GAITHERSBURG, MD
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer GAITHERSBURG, MD, November 27, 2018 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as i
Read more →ALTAltimmune Appoints Vipin K. Garg, Ph.D. as President and Chief Executive Officer
Altimmune Appoints Vipin K. Garg, Ph.D. as President and Chief Executive Officer
Read more →ALTAltimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update GAITHERSBURG, Maryland, November 13, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended Se
Read more →ALTAltimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
GAITHERSBURG, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer will provide a corporate overview at the Dawson James Securities 4th Annual Sm
Read more →ALTAltimmune Announces $25 million Registered Direct Offering GAITHERSBURG, MD
Altimmune Announces $25 million Registered Direct Offering GAITHERSBURG, MD, October 8, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with several institutional investors for the purchas
Read more →ALTAltimmune Closes on $16.9 Million in Funding
$12 million underwritten public offering closed October 2 $4.9 million registered direct offering closed September 26 GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it closed the p
Read more →ALTAltimmune Announces Pricing of $12 Million Underwritten Public Offering
GAITHERSBURG, Md., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of common units and pre-funded units for a combined total of 2,400,000 units. Each comm
Read more →ALTAltimmune Announces $4.9 million Registered Direct Offering of Common Stock GAITHERSBURG, MD
Altimmune Announces $4.9 million Registered Direct Offering of Common Stock GAITHERSBURG, MD, September 24, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several institutional invest
Read more →ALTAltimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield Development New funding will allow examination of mucosal immune response and additional vaccine characterization GAITHERSBURG, MD
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield Development New funding will allow examination of mucosal immune response and additional vaccine characterization GAITHERSBURG, MD, September 24, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-sta
Read more →ALTAltimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine Six-month data demonstrates: A statistically superior mucosal immune response providing a first line of defense
Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine Six-month data demonstrates: GAITHERSBURG, MD, September 4, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional
Read more →ALTAltimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study Studies funded by
Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 GAITHERSBURG, MD, August 31, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase 1 study of NasoShield under investigation as a pote
Read more →ALTAltimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast scheduled for tomorrow
Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast scheduled for tomorrow, August 15, 2018, at 8:30am ET GAITHERSBURG, MD, August 14, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company
Read more →ALTAltimmune to Announce Second Quarter 2018 Financial Results on August 15
GAITHERSBURG, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended June 30, 2018 before the market open and host a conference call
Read more →ALTAltimmune Restructures Financing Agreement with Substantially All of the Remaining Series B Investors GAITHERSBURG, MD
Altimmune Restructures Financing Agreement with Substantially All of the Remaining Series B Investors GAITHERSBURG, MD, July 12, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has en
Read more →ALTAltimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors
GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into agreements with substantially all of the remaining investors in its Series
Read more →ALTAltimmune Restructures Financing Agreement
Altimmune Restructures Financing Agreement GAITHERSBURG, Md., June 22, 2018 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into an agreement with the lead inves
Read more →ALTAltimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast scheduled for tomorrow, May 16 at 8:30am
Altimmune Announces First Quarter 2018 Financial Results and Provides Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET GAITHERSBURG, MD, May 15, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial re
Read more →ALTAltimmune to Announce First Quarter 2018 Financial Results on May 16
GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on W
Read more →ALTAltimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection
NasoVAX intranasal influenza vaccine demonstrated strong cellular immune response and 100% seroprotection HepTcell vaccine was well tolerated but T-cell immunogenicity results were inconclusive GAITHERSBURG, Md., March 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT),
Read more →ALTAltimmune to Participate at the H.C. Wainwright Global Life Sciences Conference
GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Con
Read more →ALTAltimmune to Announce Year End 2017 Financial Results on March 29
GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference c
Read more →ALTAltimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
Single dose of vaccine showed 67% survival rate and 100% survival rate after two doses GAITHERSBURG, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced data from a pre-clinical study comparing SparVa
Read more →ALTAltimmune to Participate at Two Investor Conferences in March
GAITHERSBURG, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the
Read more →ALTAltimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.
Patent Will Specifically Cover Prophylactic and Post-Exposure Use of NasoShield in the U.S. Patents with Similar Protection Already Issued in Europe and Japan GAITHERSBURG, Md., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics
Read more →ALTAltimmune to Participate at the Noble Capital 14th Annual Investor Conference
GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at NobleCon14 - Noble Capital Markets’ Fourt
Read more →ALTAltimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors
Current Chairman, David Drutz, M.D., remains Chairman of Compensation Committee and Member of the Board GAITHERSBURG, Md., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the election of Mitchel Sayare
Read more →ALTAltimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 – 10, 2018
GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being h
Read more →ALTAltimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study
HepTcell well tolerated in all cohorts Initial data on secondary endpoint demonstrates T cell responses GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has completed dosing of its
Read more →ALTAltimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial
145 Patients to be enrolled Data expected in the second quarter of 2018 Study will be fully-funded by BARDA GAITHERSBURG, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitte
Read more →ALTAltimmune to Present at the 29th Annual Piper Jaffray Conference
GAITHERSBURG, Md., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29th Annual Piper Jaffra
Read more →ALTAltimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update Initiated a Phase 2 clinical trial with NasoVAX vaccine with initial data expected in first quarter 2018 Completed enrollment in its
Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update Initiated a Phase 2 clinical trial with NasoVAX vaccine with initial data expected in first quarter 2018 Completed enrollment in its Phase 1 HepTcell clinical trial with data expected in fou
Read more →ALTAltimmune to Announce Third Quarter 2017 Financial Results on November 9
GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the three and nine months ended September 30, 2017 after the market close on Thursday, Novem
Read more →ALTAltimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment
60 Patients to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that they have been cleared by the FDA to initiate their Phase
Read more →ALTAltimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference
GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Ladenburg Thalmann 3rd
Read more →ALTAltimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference
GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Rodman & Renshaw 19th A
Read more →ALTAltimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial
60 volunteers to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) ap
Read more →ALTAltimmune Closes Series B Preferred Stock Offering GAITHERSBURG, MD
Altimmune Closes Series B Preferred Stock Offering GAITHERSBURG, MD, August 21, 2017 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has closed its offering of approximately 15,656 shares of Series B convertible preferred stock and
Read more →ALTAltimmune Announces $14.7 Million Series B Preferred Stock Offering GAITHERSBURG, MD
Altimmune Announces $14.7 Million Series B Preferred Stock Offering GAITHERSBURG, MD, August 17, 2017 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing
Read more →ALTSUPPLEMENTAL DISCLOSURES RELATING TO ALTIMMUNE, INC. Company Overview Altimmune, Inc., a Delaware corporation ( we, us, our, Altimmune or the Company ) is a clinical stage immunotherapeutics company focused on the develo
SUPPLEMENTAL DISCLOSURES RELATING TO ALTIMMUNE, INC. Delaware corporation ( we, us, our, Altimmune or the Company ) is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and trea
Read more →ALTAltimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update Completed merger with PharmAthene, began trading on NASDAQ as Altimmune, Inc. (ALT) Remains on track to initiate Phase 2 trial in Na
Altimmune Announces Second Quarter 2017 Financial Results and Provides Completed merger with PharmAthene, began trading on NASDAQ as Altimmune, Inc. (ALT) Remains on track to initiate Phase 2 trial in NasoVAX in Third Quarter HepTcell Phase 1 clinical trial ongoing in the UK a
Read more →ALTAltimmune to Announce Second Quarter 2017 Financial Results on August 10
GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the three and six months ended June 30, 2017 before the market open, and host a conference cal
Read more →ALTAltimmune to Provide Corporate Update at the BIO International Convention
GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the BIO International Conven
Read more →ALTAltimmune Promotes Dr. Sybil Tasker to Chief Medical Officer GAITHERSBURG, MD.
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer GAITHERSBURG, MD., May 16, 2017 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to the position of Chief Medical Officer. D
Read more →ALTAltimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, May 10, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell. Nas
Read more →ALTMatthew Duffy Investor Relations 212-915-0685 matthew@lifesciadvisors.com FOR IMMEDIATE RELEASE Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases Gaith
matthew@lifesciadvisors.com Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases Gaithersburg, MD, May 4, 2017 - Altimmune, Inc. (Nasdaq: ALT) announced today the completion of its merger with PharmAthene, Inc., effecti
Read more →ALTAltimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trad
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2568 mcarey@rxir.com PharmAthene Reports First Quarter 2017 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2568 PharmAthene Reports First Quarter 2017 Financial and Operational Results 3, 2017 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and
Read more →ALTfor PharmAthene, Inc.: Contact for Altimmune, Inc.: Melody Carey Matthew Duffy Investor Relations Investor Relations 917-322-2571 mcarey@rxir.com 212-915-0685 matthew@lifesciadvisors.com FOR IMMEDIATE RELEASE Pha
Contact for PharmAthene, Inc.: Contact for Altimmune, Inc.: Melody Carey Matthew Duffy Investor Relations Investor Relations 917-322-2571 mcarey@rxir.com 212-915-0685 matthew@lifesciadvisors.com PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq
Read more →ALTAltimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
GAITHERSBURG, Md., March 28, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutics company, today announced that the Company was awarded a contract modification to their previously announced contract. Under the U.S. Biomedical Advanced Research and Develop
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2568 mcarey@RxIR.com PharmAthene Reports Year-End 2016 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2568 PharmAthene Reports Year-End 2016 Financial and Operational Results ANNAPOLIS, MD - March 14, 2017 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported
Read more →ALTPharmAthene Reports Year-End 2016 Financial and Operational Results
PharmAthene Reports Year-End 2016 Financial and Operational Results
Read more →ALTPharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune
PharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune
Read more →ALTMerger Overview January 2017 FORWARD - LOOKING STATEMENT DISCLOSURE Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, tre nds, or strategies and
Merger Overview January 2017 FORWARD - LOOKING STATEMENT DISCLOSURE Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, tre nds, or strategies and other financial and business matters, including without lim
Read more →ALTfor PharmAthene, Inc.: Contact for Altimmune, Inc.: Melody A. Carey Bill Enright Investor Relations President and Chief Executive Officer 917-322-2571 240-654-1450 mcarey@rxir.com enright@al
Contact for PharmAthene, Inc.: Contact for Altimmune, Inc.: Melody A. Carey Bill Enright Investor Relations President and Chief Executive Officer 917-322-2571 240-654-1450 mcarey@rxir.com enright@altimmune.com PharmAthene and Altimmune Announce Merger to Create Immunotherapeuti
Read more →ALTPharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
Read more →ALTAltimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016
GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect low frequency antigen-specific T cells in HepTcell trial participants was accepted
Read more →ALTAltimmune to Present at the 28th Annual Piper Jaffray Healthcare Conference
GAITHERSBURG, Md., Nov. 18, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 28th Annual Piper Jaffray Healthcare Conference to be held November 29 - 30, 2016 in New York, NY. Bill Enr
Read more →ALTPharmAthene Declares $2.91 Special Cash Dividend on Common Stock
PharmAthene Declares $2.91 Special Cash Dividend on Common Stock
Read more →ALTPharmAthene Receives Final Payment from SIGA of $83.9 Million
PharmAthene Receives Final Payment from SIGA of $83.9 Million
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Reports Third Quarter 2016 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Reports Third Quarter 2016 Financial and Operational Results ANNAPOLIS, MD - November 4, 2016 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today r
Read more →ALTPharmAthene Reports Third Quarter 2016 Financial and Operational Results
PharmAthene Reports Third Quarter 2016 Financial and Operational Results
Read more →ALTAltimmune Announces Poster Presentation of HepTcell Program at 2017 Keystone Symposia Conference
GAITHERSBURG, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that a poster detailing the design and preclinical evaluation of its HepTcell immunotherapeutic for the treatment of chronic hepatitis B infection wil
Read more →ALTPharmAthene Announces Receipt of Payments from SIGA
PharmAthene Announces Receipt of Payments from SIGA
Read more →ALTAltimmune Announces Addition of Christine Brennan to Board of Directors
GAITHERSBURG, Md., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Christine Brennan, PhD, Principal at Novartis Venture Fund, has joined its Board of Directors effective immediately. Dr. Brennan replaces Floren
Read more →ALTAltimmune to Present at 18th Annual Rodman & Renshaw Global Investment Conference
GAITHERSBURG, Md., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11 - 13, 2016 in New York, NY
Read more →ALTPharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
Read more →ALTPharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
Read more →ALTPharmAthene Reports Second Quarter 2016 Financial and Operational Results
PharmAthene Reports Second Quarter 2016 Financial and Operational Results
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Reports Second Quarter 2016 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Reports Second Quarter 2016 Financial and Operational Results ANNAPOLIS, MD - August 4, 2016 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today re
Read more →ALTAltimmune Receives BARDA Contract of Up to $120.2 Million to Fund Clinical Development of First-In-Class Anthrax Vaccine Candidate NasoShield
GAITHERSBURG, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that the Company was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Auth
Read more →ALTAltimmune to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
GAITHERSBURG, Md., July 12, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Cantor Fitzgerald’s 2nd Annual Healthcare Conference to be held July 12-13, 2016 in New York, NY. Bill Enright,
Read more →ALTPharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline
PharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Reports First Quarter 2016 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Reports First Quarter 2016 Financial and Operational Results 9, 2016 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and
Read more →ALTAltimmune to Participate in Two Upcoming Conferences
GAITHERSBURG, Md., May 03, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be participating in two upcoming industry conferences. Altimmune will present at the the 18th Annual TIDES: Oligonucleotide and P
Read more →ALTAltimmune Announces Participation in Vaccine Development Panel at the Annual Regional Biotech Forum
GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will participate in a vaccine development panel at the Annual Regional Biotech Forum. The panel will take
Read more →ALTAltimmune Expands Clinical Development Team
Appoints Sybil Tasker as Senior Vice President, Clinical Research and Development Names Efe Egharevba as Head of Clinical Project Management GAITHERSBURG, Md., April 05, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced the ex
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA ANNAPOLIS, MD - March 11, 2016 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical counte
Read more →ALTPharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA
PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA
Read more →ALTAltimmune to Present at Two Upcoming Conferences
GAITHERSBURG, Md., March 01, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following conferences: 23rd Annual Future Leaders in the Biotech Industry Conf
Read more →ALTAltimmune Announces Presentation at BIO CEO & Investor Conference
GAITHERSBURG, Md., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY. Bill Enright, Chief Executiv
Read more →ALTAltimmune Announces Presentation at Biotech Showcase 2016
GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco, CA. Bill Enright, Chief Executive Offi
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards ANNAPOLIS
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards ANNAPOLIS, MD - November 25, 2015 - PharmAthene, Inc. (NYSE MKT: PIP), announced today that its Board of Directors has adopt
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Reports Third Quarter 2015 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Reports Third Quarter 2015 Financial and Operational Results ANNAPOLIS, MD - November 6, 2015 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threat
Read more →ALTAltimmune Chief Scientific Officer to Present at Two Premier Vaccine Conferences
GAITHERSBURG, MD--(Marketwired - Oct 12, 2015) - Altimmune, Inc. (formerly Vaxin Inc.), a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The
Read more →ALTAltimmune CEO to Present at the 2015 Ladenburg Thalmann Healthcare Conference in New York City
GAITHERSBURG, MD--(Marketwired - Sep 28, 2015) - Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that CEO Bill Enright will present at the 2015 Ladenburg Thalmann Healthcare Conference to be held tomorrow at the Sofitel H
Read more →ALTVaxin Changes Company Name to Altimmune
GAITHERSBURG, MD--(Marketwired - Sep 1, 2015) - Vaxin Inc. , a clinical stage immunotherapy and vaccine company, today announced that it has changed its corporate name to Altimmune, Inc. Vaxin was founded in 1997 to pioneer new-generation vaccine technologies and products. Since
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PharmAthene Reports Second Quarter 2015 Financial and Operational Results ANNAPOLIS, MD
Rx Communications Group, LLC Phone: (917) 322-2571 PharmAthene Reports Second Quarter 2015 Financial and Operational Results ANNAPOLIS, MD - August 5, 2015 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats
Read more →ALTMelody Carey Rx Communications Group, LLC Phone: (917) 322-2571 mcarey@RxIR.com PHARMATHENE REPORTS FIRST QUARTER 2015
Rx Communications Group, LLC Phone: (917) 322-2571 PHARMATHENE REPORTS FIRST QUARTER 2015 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - May 7, 2015 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemic
Read more →ALTMelody A. Carey Rx Communications Group, LLC (917) 322- 2571 mcarey@RxIR.com PHARMATHENE REPORTS YEAR-END 2014 FINANCIAL AND OPERATIONAL RESULTS; ANNOUNCES PLAN TO REALIGN OPERATIONAL RESOU
Rx Communications Group, LLC PHARMATHENE REPORTS YEAR-END 2014 FINANCIAL AND OPERATIONAL RESULTS; ANNOUNCES PLAN TO REALIGN OPERATIONAL RESOURCES 2014 Operational Highlights ANNAPOLIS, MD - March 9, 2015 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing me
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable T
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE PROVIDES THIRD QUARTER 2014 OPERATIONAL AND FINANCIAL UPDATE Recent Operational Highlig
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE PROVIDES THIRD QUARTER 2014 OPERATIONAL AND FINANCIAL UPDATE Recent Operational Highlights ANNAPOLIS, MD - November 6, 2014 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical counte
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: 410-269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE AWARDED CONTRACT OF UP TO $28.1
Stacey.Jurchison@PharmAthene.com AWARDED CONTRACT OF UP TO $28.1 MILLION TO DEVELOP NEXT GENERATION THERMOSTABLE ANTHRAX VACCINE MD - September 10, 2014 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemica
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS SECOND QUARTER 2014
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS SECOND QUARTER 2014 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - August 4, 2014 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2014
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2014 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - May 8, 2014 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and ch
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE UPDATES STATUS OF ANTHRAX VACCINE CONTRACT ANNAPOLIS, MD - April 7, 2014 - PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS)
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2013
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2013 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - March 11, 2014 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chem
Read more →ALTTheraclone Provides Update on BARDA Funding Proposal for TCN-032 for Serious and Pandemic Flu Seattle, WA
Theraclone Provides Update on BARDA Funding Proposal for TCN-032 for Serious and Pandemic Flu Seattle, WA - November 27, 2013 - Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that it has received notification from the Biom
Read more →ALTAN IMPORTANT REMINDER! Dear PharmAthene Stockholder: As you know, we are holding a special meeting of stockholders to vote on proposals related to our proposed merger with Theraclone Sciences. The meeting is scheduled fo
AN IMPORTANT REMINDER! Dear PharmAthene Stockholder: As you know, we are holding a special meeting of stockholders to vote on proposals related to our proposed merger with Theraclone Sciences. The meeting is scheduled for December 3, 2013 at Dentons US LLP, 1301 K Street, NW,
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS THIRD QUARTER 2013 FINANCIAL AND OPERATIONAL RESULTS Recent Highlights On track
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS THIRD QUARTER 2013 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - November 7, 2013 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological an
Read more →ALTTheraclone Sciences' Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease -- Study Findings Published by Collaborators in Nature -- --Theraclone Seeking Licensees and Strategic Alliances for th
Theraclone Sciences' Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease --Study Findings Published by Collaborators --Theraclone Seeking Licensees and Strategic Alliances for the HIV Program-- Seattle, WA - November 4, 2013 - Theraclone Sciences
Read more →ALTTurning the Human Repertoire's Most Potent Antibodies into Superior Therapeutics Bio Investor Forum San Francisco
Turning the Human Repertoire's Most Potent Antibodies into Superior Therapeutics Bio Investor Forum San Francisco October 8, 2013 Clifford J. Stocks Chief Executive Officer 2 Theraclone / PharmAthene Theraclone Sciences, Inc., a monoclonal antibody discovery and development comp
Read more →ALTTheraclone Sciences Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013 Seattle, WA
Theraclone Sciences Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013 Seattle, WA - September 11, 2013 - Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, toda
Read more →ALTTheraclone Sciences Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection Seattle, WA
Theraclone Sciences Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection Seattle, WA - September 10, 2013 - Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that it has dosed
Read more →ALTRodman & Renshaw Annual Global Investment Conference September 9, 2013
Rodman & Renshaw Annual Global Investment Conference September 9, 2013 Safe Harbor Statement Except for the historical information presented herein, matters discussed may constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act o
Read more →ALTFor PharmAthene, Inc. : Stacey Jurchison Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com For Theraclone Sciences, Inc. Michelle Avery Phone: (781) 235-3060 mavery@macbiocom.com FOR IMMEDIATE RELEASE: PHAR
FOR IMMEDIATE RELEASE: PHARMATHENE FILES REGISTRATION STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION ANNAPOLIS, MD, September 9, 2013 - PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exc
Read more →ALTTheraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study Seattle, WA
Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Seattle, WA - September 8, 2013 - Theraclone Sciences, Inc., a therapeutic antibody discovery and developme
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE PRESENTS NEW SPARVAX DATA AT THE BACILLUS - ACT 2013
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE PRESENTS NEW SPARVAX AT THE BACILLUS - ACT 2013 INTERNATIONAL ANNAPOLIS, MD - September 6, 2013 - PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from the Company's SparVax next-generation an
Read more →ALTTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT PIP - Q2 2013 PharmAthene, Inc. Earnings Conference Call EVENT DATE/TIME: AUGUST 07, 2013 / 08:30PM GMT 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 20
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT PIP - Q2 2013 PharmAthene, Inc. Earnings Conference Call EVENT DATE/TIME: AUGUST 07, 2013 / 08:30PM GMT CORPORATE PARTICIPANTS Jurchison PharmAthene, Inc. - Director -- Corporate Communications Richman PharmAthene, Inc. - Presiden
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS SECOND QUARTER 2013 FINANCIAL AND OPERATIONAL RESULTS Recent Highlights Plans t
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS SECOND QUARTER 2013 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - August 7, 2013 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and
Read more →ALTFDA Lifts Clinical Hold On PharmAthene's SparVax Anthrax Vaccine Program ANNAPOLIS, Md.
FDA Lifts Clinical Hold On PharmAthene's SparVax Anthrax Vaccine Program ANNAPOLIS, Md., May 30, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U
Read more →ALTDelaware Supreme Court Affirms Lower Court's Ruling That SIGA Technologies Breached Its Contractual Obligation To Negotiate In Good Faith Delaware High Court Confirms Availability of Expectancy Damages ANNAPOLIS, Md.
Court Affirms Lower Court's Ruling That SIGA Technologies Breached Its Contractual Obligation To Negotiate In Good Faith High Court Confirms Availability of Expectancy Damages May 26, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) today announced that the Delaware Supre
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2013
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2013 FINANCIAL AND OPERATIONAL RESULTS ANNAPOLIS, MD - May 8, 2013 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and ch
Read more →ALTStacey.Jurchison@PharmAthene.com
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2012 FINANCIAL AND OPERATIONAL RESULTS Year-End 2012 Highlights ANNAPOLIS, MD - March 13, 2013 - PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures ag
Read more →ALTRodman & Renshaw 14 th Annual Healthcare Conference
1 Rodman & Renshaw 14 th Annual Healthcare Conference September 10, 2012 2 Safe Harbor Statement This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Recent Highlights PharmAthene plans to co
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS SECOND QUARTER 2012 ANNAPOLIS, MD - August 7, 2012 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Recent Highlights Achieved positive quarte
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2012 ANNAPOLIS, MD - May 8, 2012 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE SECURES $7.5
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE SECURES $7.5 MILLION CREDIT GE CAPITAL HEALTHCARE FINANCIAL SERVICES ANNAPOLIS, MD - April 3, 2012 - PharmAthene, Inc. (NYSE Amex: PIP) today announced that it has secured $7.5 million in senior secured credi
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2011 FINANCIAL AND OPERATIONAL RESULTS Year-End 2011 Highlights Won fa
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2011 FINANCIAL AND OPERATIONAL RESULTS Year-End 2011 Highlights ANNAPOLIS, MD - March 8, 2012 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures ag
Read more →ALTUnassociated Document FOR IMMEDIATE RELEASE Contact: Stacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS THIRD QUARTER 2011 FINANCIAL AND OPERATING RESULTS Third
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS THIRD QUARTER 2011 FINANCIAL AND OPERATING RESULTS Third Quarter Highlights ANNAPOLIS, MD - November 9, 2011 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasur
Read more →ALTStacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE APPOINTS BRIAN A. MARKISON TO THE COMPANY'S
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE APPOINTS BRIAN A. MARKISON TO THE COMPANY'S BOARD OF DIRECTORS ANNAPOLIS, MD - September 26, 2011 -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biologic
Read more →ALTUnassociated Document PharmAthene Reports Second Quarter 2011 Financial and Operating Results ANNAPOLIS, Md.
PharmAthene Reports Second Quarter 2011 Financial and Operating Results ANNAPOLIS, Md., Aug. 10, 2011 -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operating re
Read more →ALTUnassociated Document FOR IMMEDIATE RELEASE Contact : Stacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com pharmathene announces $6.5 million registered direct offering ANNAPOLIS, MD
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com pharmathene announces $6.5 million registered direct offering ANNAPOLIS, MD - June 10, 2011 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical thre
Read more →ALTUnassociated Document FOR IMMEDIATE RELEASE Contact: Stacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2011
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS FIRST QUARTER 2011 FINANCIAL AND OPERATING RESULTS ANNAPOLIS, MD - May 11, 2011 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chem
Read more →ALTUnassociated Document FOR IMMEDIATE RELEASE Contact: Stacey Jurchison PharmAthene, Inc. Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2010
Phone: (410) 269-2610 Stacey.Jurchison@PharmAthene.com PHARMATHENE REPORTS YEAR-END 2010 FINANCIAL AND OPERATING RESULTS ANNAPOLIS, MD - March 28, 2011 - PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemica
Read more →Competitive Position
How ALT ranks across every disease it competes inCompetitive Position is a premium feature
See how ALT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial